Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (17019)	7/7/2004 9:37:43 AM
From: Edscharp	Respond to of 17367

RobertK, Blue; I still remember back a few years ago when this board had dozens of excellent posters on it. Now they are all gone. But fortunately we still have the two of you. It's a great act, though. Keep up the good work. Both of you are funnier than Abbott and Costello (not Jack). Are you guys available for kid's birthday parties? Lol.

To: Robert K. who wrote (17019)	7/7/2004 10:13:48 AM
From: Bluegreen	Respond to of 17367

Look at the combination of anti-lfa-1 and others.>>>>>http://www.pnas.org/cgi/content/abstract/91/15/7291

To: Robert K. who wrote (17019)	7/7/2004 10:46:27 PM
From: Bluegreen	Respond to of 17367

WOW!!!!!!!!!!!!!!!>>>>>>>http://biz.yahoo.com/bw/040707/75856_1.html

To: Robert K. who wrote (17019)	7/7/2004 10:53:53 PM
From: Bluegreen	Respond to of 17367

Bob, you know if DNA signs up 10,000 patients for Raptiva that is around 140 MILLION in sales a year figuring 14,000 dollars a year per patient.

To: Robert K. who wrote (17019)	7/7/2004 10:57:56 PM
From: Bluegreen	Respond to of 17367

So, how do you like this?>>>>>>During an analyst meeting held by Chiron Corporation on June 23rd, Chiron announced the first monoclonal antibody target for cancer, CD40, that it will co-develop with XOMA. XOMA and Chiron entered into a multi-product collaboration agreement in February of 2004 for the development and commercialization on antibody products for the treatment of cancer. Chiron and XOMA plan to file an Investigational New Drug (IND) application to the U.S. FDA for the anti-CD40mAb compound by the end of 2004. On July 6th, Chiron announced the acquisition of Sagres Discovery, a privately held discovery stage company based in Davis, California, that specializes in the discovery and validation of oncology targets. Under the acquisition, Chiron reportedly will have access to all of Sagres' proprietary technology in the area of oncology. Further review of these targets is expected to identify additional antibody target candidates that will be used as part of XOMA's and Chiron's antibody product candidate program for the treatment of cancer.<<<<<<<<<

To: Robert K. who wrote (17019)	7/7/2004 11:48:29 PM
From: Bluegreen	Respond to of 17367

Bob, can you imagine what would happen if Genentech and Xoma did a sepsis trial involving Raptiva and Neuprex???>>>>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=14744817